Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy

Int J Nanomedicine. 2019 Oct 21;14:8321-8344. doi: 10.2147/IJN.S218085. eCollection 2019.


Contrast agents (CAs) play a crucial role in high-quality magnetic resonance imaging (MRI) applications. At present, as a result of the Gd-based CAs which are associated with renal fibrosis as well as the inherent dark imaging characteristics of superparamagnetic iron oxide nanoparticles, Mn-based CAs which have a good biocompatibility and bright images are considered ideal for MRI. In addition, manganese oxide nanoparticles (MONs, such as MnO, MnO2, Mn3O4, and MnOx) have attracted attention as T1-weighted magnetic resonance CAs due to the short circulation time of Mn(II) ion chelate and the size-controlled circulation time of colloidal nanoparticles. In this review, recent advances in the use of MONs as MRI contrast agents for tumor detection and diagnosis are reported, as are the advances in in vivo toxicity, distribution and tumor microenvironment-responsive enhanced tumor chemotherapy and radiotherapy as well as photothermal and photodynamic therapies.

Keywords: MRI; contrast agent; manganese oxide nanoparticles; multimodal imaging; tumor therapy.

Publication types

  • Review

MeSH terms

  • Contrast Media / chemistry*
  • Humans
  • Magnetic Resonance Imaging / methods*
  • Manganese Compounds / chemistry*
  • Multimodal Imaging / methods*
  • Nanoparticles / chemistry*
  • Neoplasms / diagnosis
  • Neoplasms / diagnostic imaging*
  • Neoplasms / therapy*
  • Oxides / chemistry*


  • Contrast Media
  • Manganese Compounds
  • Oxides
  • manganese oxide